Stock listing
Frankfurt:PGO0 Prostatype Genomics AB Aktie
German listing (Frankfurt) of Prostatype Genomics AB · home listing Stockholm:PROGEN
Follow Prostatype Genomics AB into a list and get an email when it puts out news.
Share price · FWB:PGO0
€0.0050 EUR -0.0018 (-26.5%)
Close on Oct 30, 2026
- Day range
- €0.0048 – €0.0072 EUROct 30, 2026
- Market cap
- €777,842 EURAt the close on Oct 30, 2026 · price × 155.6M shares outstanding
Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| Stockholm:PROGEN · Home | 0.108 SEK | +0.001 (+0.5%) | 1,388,204 | 0.107 | 0.108 | 0.100 | 0.107 | Close on Oct 30, 2026 |
| Frankfurt:PGO0 | €0.0050 EUR | -0.0018 (-26.5%) | — | €0.0048 | €0.0072 | €0.0048 | €0.0068 | Close on Oct 30, 2026 |
- Ticker
- Frankfurt:PGO0
- Asset type
- Stock
- Sector
- Health care
- Industry
- Diagnostics & research services
- Exchange
- Frankfurt
- Currency
- EUR
What changed lately
Latest news release · Sep 17, 2026
Prostatype Genomics AB receives approximately SEK 12.5 million through the exercise of warrants of series TO6
Latest news
Financings
New shares through exercise of warrants of series TO6
Sep 17, 2026 · US$1.27M
Closed: SEK 12.5M raised · SEK 0.1 a share · Vator Securities AB +2
Dealers: Vator Securities AB, Navia Corporate Finance AB, Birchtree Advisory AB
Buyers: Vator Securities AB (8,156,289 shares at SEK 0.10 in the Directed Share Issue (underwriting and compensation shares))
Insiders: Letters of intent from the Board of Directors, management and other warrant holders corresponding to approximately SEK 2.27 million
Use of proceeds: Liquidity and financial position of the company
Rights offering of units (shares and warrants of series TO6 and TO7)
Aug 3, 2026 · US$4.88M
Closed: SEK 47.4M raised · SEK 0.1 a unit · Warrants at SEK 0.1 · Navia Corporate Finance AB +2
Dealers: Navia Corporate Finance AB (co-lead), Birchtree Advisory AB (co-lead), Vator Securities AB
Insiders: Subscription commitments from existing major shareholders, including members of the Board of Directors, totalling approximately SEK 9.2 million
Use of proceeds: Accelerate commercialization of Prostatype, strengthen presence in prioritized markets and continue company development
Update Jul 8, 2026 · Update Jul 9, 2026 · Update Jul 21, 2026 · Closed Jul 27, 2026 · Update Aug 3, 2026
Prostatype Genomics AB on 6ix
- Sector
- Health care
- Industry
- Diagnostics & research services
- News releases
- 15 in the last 12 months · 21 in all · newest Sep 17, 2026 · oldest 2025
Where Prostatype Genomics AB is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| Stockholm:PROGEN · Home listing | Stockholm | Sweden | SEK |
| OTC:PGABF | OTC | United States | USD |
| Frankfurt:PGO0 · This page | Frankfurt | Germany | EUR |
Log in to ask 6ix AI your own questions about Prostatype Genomics AB.